Targeted CAR-macrophage therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment using your own immune cells, called macrophages, that are specially designed to attack cancer cells based on certain markers (like HER2). It is for people with advanced solid tumors who have already tried other treatments and need a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced solid cancer that has been tested for certain markers (HER2, PSMA, or FAP) and your cancer is no longer responding to standard treatments.
- You are able to care for yourself (ECOG score 0-2) and expected to live at least 3 more months.
- Your blood counts, liver, kidney, heart, and pancreas function are within safe limits.
- You have at least one tumor that can be measured on scans, and you have good veins for a procedure called apheresis (blood cell collection).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy using your own immune cells (macrophages) that have been engineered to fight pancreatic cancer. The study is for patients with advanced pancreatic cancer that has spread or cannot be surgically removed, and whose cancer has not responded well to prior treatments.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new cell therapy called CAR-DC for people with advanced solid tumors that have certain markers on their cells. It aims to see if it is safe and works against cancers like lung, liver, stomach, or colorectal cancer that haven't responded to standard treatments.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.